Skip to main content
. 2023 Jul 21;20:169. doi: 10.1186/s12974-023-02850-6

Table 1.

Cohort clinical, demographic, and genetic information

EOAD LOAD Control
Number 912 492 504
Sex, n (%)
 Female 425 (46.6) 243 (49.39) 282 (56)
 Male 487 249 222
Age at onset
 Mean (SD) 58 (5.16) 71 (5.34) n/a
 Range 28–65 66–90 n/a
Age at inclusiona
 Mean (SD) 64 (5.7) 76 (5.46) 82.5 (6.8)
 Range 30–90 66–97 59–100
 Disease duration (SD) 5.7 (3.6) 4.5 (2.9) n/a
 MMSE score (SD) 16.34 (10) 18 (9.23) 27.4 (5.5)
APOE status, n (%)
 ε4 (−) 402 184 400
 ε4 (+) 491 (55) 289 (61) 93 (18.9)
CLU rs11136000, n (%) (MAF_A = 0.3659, MAF_U = 0.4)
 CC 370 (40.57) 204 (41.46) 172 (34.68)
 TC 412 (45.18) 227 (46.14) 242 (48.79)
 TT 130 (14.25) 61 (12.4) 82 (16.53)
CLU rs9331888, n (%) (MAF_A = 0.29, MAF_U = 0.28)
 CC 462 (50.77) 236 (51.42) 254 (51.84)
 GC 374 (41.1) 177 (38.56) 201 (41.02)
 GG 74 (8.13) 46 (10.02) 35 (7.14)
CR1 rs6656401, n (%) (MAF_A = 0.1958, MAF_U = 0.1735)
 GG 596 (65.49) 290 (63.18) 336 (68.71)
 AG 285 (31.32) 145 (31.59) 137 (28.02)
 AA 29 (3.19) 24 (5.23) 16 (3.27)
CR1 rs6691117, n (%) (MAF_A = 0.1822, MAF_U = 0.1792)
 AA 593 (65.02) 332 (67.48) 337 (68.08)
 GA 299 (32.79) 148 (30.08) 144 (29.09)
 GG 20 (2.19) 12 (2.44) 14 (2.83)
C1S rs3919533, n (%) (MAF_A = 0.1545, MAF_U = 0.1667)
 TT 659 (72.26) 336 (68.43) 345 (68.86)
 CT 237 (25.99) 146 (29.74) 138 (27.54)
 CC 16 (1.75) 9 (1.83) 18 (3.6)
CFH rs6664877, n (%) (MAF_A = 0.175, MAF_U = 0.1549)
 CC 575 (65.64) 309 (69.44) 313 (71.62)
 TC 286 (32.65) 124 (27.87) 114 (26.1)
 TT 15 (1.71) 12 (2.69) 10 (2.28)

EOAD early onset AD, LOAD late onset AD, MMSE mini mental state examination, MAF_A minor allele frequency in individuals with AD, MAF_U minor allele frequency in control individuals

aEOAD and LOAD subjects were significantly younger than control subjects (p < 0.0001)